Inviragen | Series A $15M and M&A

Posted in CO Private: InViragen, Series A

Inviragen (Ft. Collins, CO) a preclinical-stage vaccine company focused on emerging global infectious diseases, closed a $15M Series A financing and in the process merged the assets of Singapore-based SingVax. Participants in the round include Charter Life Sciences, Venture Investors, Bio*One Capital and Phillip Private Equity. This initial round of institutional capital comes on the [...]

4532009-10-07+13%3A11%3A00admin

Tape-Delay from the RMLSIC | Part Deux

Posted in CO Private: ApopLogic, CO Private: BioAmps, CO Private: GlobeImmune, CO Private: InViragen, CO Private: miRagen, CO Private: Myocept, CO Private: Western, MT Private: LigoCyte

Continuing here with Part Deux of the Rocky Mountain Life Science Investor Conference presenting companies. Yesterday CLSDF posted the Diagnostic oriented entities, today we feature the biopharma folks. ApopLogic – Aurora, CO-based AL is a biopharmaceutical company focused on the discovery, and development of therapeutic products that target apoptotic cell death pathways found in cancers, [...]

4412009-09-22+02%3A55%3A00admin

InViragen: Two Steps Forward

Posted in CO Private: InViragen

InViragen (Ft. Collins) is committed to developing life-saving vaccines to protect against emerging infectious diseases worldwide and continues on a very positive trajectory. Building upon last years $2.7M NIH Dengue vax grant InViragen has now confirmed financial support from the Pediatric Dengue Vaccine Initiative. This non-dilutive financing will enable the manufacture of the Dengue vax, [...]

260InViragen%3A+Two+Steps+Forward2007-11-26+15%3A53%3A00admin

InViragen Making Inroads

Posted in CO Private: InViragen

Congratulations to Dr. Dan Stinchcomb, President & CEO and the entire team at InViragen (Ft. Collins) on their new partnership with the Pediatric Dengue Vaccine Initiative, to help develop and manufacture a dengue vaccine to be made widely available for the global prevention of dengue fever, the second most prevalent tropical disease after malaria. Dengue [...]

221InViragen+Making+Inroads2007-09-26+23%3A41%3A00admin

InViragen: Agreemnent with Shantha Bio

Posted in CO Private: InViragen

InViragen (Ft. Collins), who is developing vaccines against emerging world-wide diseases such as West Nile, avian influenza, plague and smallpox, has announced a vaccine manufacturing agreement with Shantha Biotechnics (Hyderabad, India) to develop their lead dengue vax product to enable completion of preclinical studies and initiate safety and efficacy clinical trials. Since winning the first [...]

1322006-11-06+16%3A50%3A00admin

InViragen: Fighting Flaviviruses

Posted in CO Private: InViragen

InViragen, LLC was formed by Dr. Dan Stinchcomb to identify promising Dengue and West Nile vaccine technologies. The business plan calls for the completion of preclinical and Phase 1 and 2 clinical development., the vaccines then will be licensed to major pharmaceutical companies for Phase 3 clinical studies, manufacturing and marketing in the US and [...]